1. INTRODUCTION {#sec1}
===============

Cardiovascular Diseases (CVD) in cancer survivors are considered to be the leading cause of prolonging their lifespan. The higher incidence and mortality rate of cardio- vascular diseases than the risk of cancer recurrence turn CVD into a challenge in patients' treatment. Heart Failure (HF) with a fifteen-fold and coronary artery disease with a ten-fold increased risk of development in cancer survivors may lead to higher mortality rates \[[@r1], [@r2]\]. Anthracyclines, a widely used chemotherapy agent with a definite survival improvement can result in cardiac toxicity presenting mainly with HF \[[@r3]\]. Thus, the higher incidence of cardiovascular disease in these patients may stem from administration of these chemotherapy agents in addition to traditional risk factors such as hypertension and dyslipidemia \[[@r4], [@r5]\]. Anthracycline-related cardiac toxicity is a dose-dependent phenomenon related to cumulative dose of drugs \[[@r6], [@r7]\] but rarely occurs after a single-dose administration \[[@r8]\]. Various mechanisms were described in the pathogenesis of anthracyclines-related cardiotoxicity, including oxidative stress, accumulation of toxic metabolites, iron metabolism alterations, disruption of energetic mechanisms, sarcomeric structure alterations and inflammatory mediators' release \[[@r9]\]. Cardiotoxicity is defined as a decrease in the LVEF of \>10% to a value \<53% as measured by two-dimensional (2D) echocardiography \[[@r10]\]. Prediction of cardiac toxicity may be crucial to prevent further cardiac injury and alter future treatments. Previous studies used cardiac biochemical markers such as Troponin T, I and B-type natriuretic peptide (BNP) and echocardiographic parameters to detect cardiac dysfunction early after treatment. These biomarkers have been described as potential predictors of early cardiac dysfunction after chemotherapy in many studies \[[@r11]-[@r13]\]. Echocardiography is also able to detect cardiac dysfunction at an early stage. Previous studies used myocardial velocities and strain as a sensitive marker of myocardial dysfunction \[[@r14]\]. A new approach, two-dimensional speckle tracking method, was also introduced and used for early detection of subclinical myocardial abnormalities \[[@r15]\]. Strain, which is another prognostic factor, was also used to identify the patients who may develop cardiac dysfunction \[[@r16]\]. To our knowledge, there were few studies, which compared the superiority of biochemical markers (such as hs-cTnI and NT-proBNP) and echocardiographic parameters for early detection of Anthracycline-related cardiac toxicity to each other. In this study, we evaluated the ability of cardiac biomarkers and 2-dimensional echocardiographic parameters to detect acute and sub-acute Anthracycline-related cardiac toxicity.

2. MATERIAL AND METHODS {#sec2}
=======================

2.1. Study Population {#sec2.1}
---------------------

A prospective cohort study from April 2017 to April 2018 was performed. Fifty-two consecutive adult patients scheduled to undergo the first course of Anthracycline-based chemotherapy at Imam Hossein hospital (Tehran, Iran) were eligible to enter the study. Patients were excluded if they were older than 70 years, had a history of cardiovascular disease, prior administration of mediastinal radiotherapy, chronic kidney disease (GFR \< 60 ml/min), liver disease (ALT or AST \>50 U/l, serum bilirubin \>1.5 mg/dl), left ventricular ejection fraction \<50% and prior or additional administration of Herceptin for breast cancer. Adriamycin was administered every 2 or 3 weeks and at least 6 courses regarding the type of malignancy. The cumulative dosage ranged from 240 to 360 mg/m^2^. Idarubicin was given for 3 days with a cumulative dosage of 36 mg/m^2^. The ethics committee of Shahid Beheshti University of Medical Sciences approved all the protocols of the current study and all the patients gave written informed consent.

2.2. Echocardiography {#sec2.2}
---------------------

All the patients underwent highly sensitive 2D echocardiographic evaluation before the treatment, 4 and 12 weeks after completion of first-course chemotherapy. All the evaluations were performed and analyzed with a Philips ultrasound system (EPIQ 7c, USA) and automated Cardiac Motion Quantification software (aCMQ) installed and by means of 2-dimensional speckle tracking echocardiography method. The following parameters were measured: Left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic volume (LVEDV), LVEF (biplane method according to modified Simpson's rule) \[[@r17]\] and longitudinal strain. The longitudinal strain was measured globally and segmentally (Fig. **[1](#F1){ref-type="fig"}**). In segmental approach, anterior, anteroseptal, lateral, posterior, inferior, and inferoseptal walls were evaluated. Normal longitudinal stress was considered 16% to 22%. As this study was designed to evaluate acute cardiac toxicity of Anthracyclines, no cardiac evaluation was performed after the last course of treatment. One cardiologist interpreted echocardiograms (intraobserver reliability of 90%) and she was blinded to patients' history, biochemical markers and types of chemotherapy drugs administered. Cardiac toxicity was defined as a decrease in the LVEF of \>10% to a value \<53% as measured by two-dimensional (2D) echocardiography. Definite diagnosis of cardiac toxicity was conducted at the end of a 12-week follow-up.

2.3. Biochemical Markers {#sec2.3}
------------------------

High-sensitive cardiac troponin I (hscTn-I) and N-terminal-pro-BNP (NT-proBNP) were cardiac markers measured in our study with a routine blood sample before the initiation and 3 weeks after completion of first-course chemotherapy, and serum level of these markers was also assessed. The hscTn-I levels were assessed by ADIVA Centaur® high sensitivity Troponin I assay kit (Siemens, Germany), and any value below 19 ng/l was considered normal. NT-proBNP was assessed by Stratus® CS Acute Care^TM^ NT-proBNP assay kit (Siemens, Germany), and any value below 300 pg/ml was considered normal.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Quantitative data were presented by mean and standard deviation (Mean ± SD). Sensitivity was plotted in function of 1-Specificity as ROC (receiver operating characteristic) curve for different cut-off points of biomarkers and echocardiographic parameters. Area under the ROC curve was used as a criterion to measure test's discriminative ability. Youden index was used to predict the optimal cut-off point for each marker. Biomarkers and echocardiographic parameters were compared for their prognostic power by means of AUC, likelihood ratio and odds ratio. Any P value ≤ 0.05 was considered significant. All the analyses were performed in Statistical Package for Social Science (SPSS) version 16.

3. RESULTS {#sec3}
==========

3.1. Patient Baseline Characteristics {#sec3.1}
-------------------------------------

Fifty-two patients (11 males, 41 female) with an average age of 44.3 (range 18-69 years) were followed after the administration of Anthracycline. Histopathologic diagnoses included breast cancer (31 patients), leukemia (5 patients) and lymphoma (16 patients). Anthracyclines administered for chemotherapy regimen were Adriamycin (49 patients; dosage ranged between 240 and 360 mg/m^2^) and Idarubicin (3 patients; dosage of 36 mg/m^2^). Echocardiography performed before the administration of Anthracyclines revealed normal LVEF (56.54±2.33, range 55-60) in all the patients. LVEF mean compared to baseline decreased to 53.94±4.57 (range 40-60 after 3 month), which reached statistical significance after 3 months (P value\<0.001). Cardiac toxicity was observed in 5 patients (9.6%) during the follow-up. Table **[1](#T1){ref-type="table"}** provides an overview of patients' clinical

characteristics. Distribution of sex, hypertension, diabetes mellitus, high lipid profile, lung disease and thyroid disease was not statistically different in the groups with and without cardiotoxicity during the follow-up. Mean age and drug dosage were not significantly different in the two groups. Table **[2](#T2){ref-type="table"}** compares the mean baseline level of cardiac biomarkers and baseline echocardiographic parameters between patients with and without cardiotoxicity. Except serum level of hs-cTnI, which was greater in patients with cardiac toxicity (P value\<0.001), all cardiac biomarkers and echocardiographic parameters were not significantly different between the two groups. Baseline levels of SLS were not significantly different in patients with cardio- toxicity and without it.

3.2. Echocardiographic Parameters {#sec3.2}
---------------------------------

After 4 weeks of follow-up, 4 patients (7.7%) reported decreased LVEF compared to baseline and LVEF decreased in 14 patients (26.9%) from 4-12 weeks of follow-up. Fifteen patients (28.8%) revealed a decrease in LVEF throughout the evaluations, while just 5 patients met the criteria of cardiac toxicity (9.6%). Although, baseline levels of SLS were not significantly different in patients with cardiotoxicity and without it, while inferoseptal, inferior, anteroseptal and anterior SLS were significantly lower at the second evaluation in patients with cardiac toxicity (P value: 0.001, 0.001, 0.054, 0.030, respectively).

†First evaluation is defined as before drug administration for both cardiac biomarkers and echocardiographical parameters. However, second evaluation is defined as after 3 weeks and after 4 weeks for cardiac biomarkers and echocardiographical paramaeters, respectively. Abbreviations: Sen: Sensitivity; Spe: Specificity; LR+: Positive likelihood ratio; GLS: Global longitudinal strain; SLS: Segmental longitudinal strain; LVEDD: Left ventricular end diastolic diameter; LVESD: Left ventricular end systolic diameter; LVEDV: Left ventricular end diastolic volume.

None of the patients had abnormal baseline GLS, while 8 patients (15.4%) revealed abnormal GLS at 4 weeks of follow-up and 50% of those with decreased GLS at the second evaluation revealed cardiac toxicity eventually. AUC for GLS ROC curve at 4 weeks of follow-up was calculated as 0.968 (P value: 0.001). Thus, GLS at the second evaluation is believed to be a good predictor for cardiac toxicity. SLS was measured and anterior, anteroseptal, lateral, posterior, inferior, and inferoseptal walls were evaluated. Inferoseptal SLS had the highest AUC value (AUC: 0.934) among different wall SLS. LVESD at first and second evaluation could predict the risk of cardiac toxicity among LVESD, LVEDD and LVEDV (AUC: 0.826, 0.528, 0.706; P value: 0.018, 0.84, 0.132, respectively). All data regarding prognostic power of echocardiographic parameters for cardiac toxicity are illustrated in Table **[3](#T3){ref-type="table"}**.

3.3. Cardiac Biomarkers {#sec3.3}
-----------------------

At initiation, 10 patients (19.2%) had more than normal hs-cTnI and 40% of these group revealed cardiac toxicity after 3 months. In patients with normal hs-cTnI, just one patient interrupted cardiac toxicity. There was a significant positive correlation between the baseline level of hs-cTnI and cardiotoxicity. In the second evaluation (3 weeks after drug administration), 38 patients (73.1%) had more than the normal level of hs-cTnI and 5 patients (13.2%) of them revealed cardiac toxicity throughout the study. None of the 14 patients with normal level of hs-cTnI at the second evaluation showed this adverse effect. Although the percentage of patients who showed cardiac toxicity in the group with more than normal hs-cTnI at second evaluation was higher than the group with normal hs-cTnI, this difference did not reach statistical significance (P value: 0.307). Both baseline and 3-week hs-cTnI had good prognostic power to predict cardiac toxicity (AUC: 0.940, 0.989, P value: 0.038, 0.020, respectively). The baseline serum level of hs-cTnI was significantly higher among patients with cardiac toxicity and remained higher in further evaluations. The best cut-off for hs-cTnI, which predicts cardiac toxicity, was measured to be 17 and 29 ng/l for the baseline and second evaluation. There was a significant correlation between hs-cTnI and EF level, even without cardiac toxicity. The mean serum level of hs-cTnI was higher in patients experiencing EF decrease at the second evaluation (20.43±4.93 and 34.47±12.04 for the patients without and with EF reduction, respectively; P-value\<0.001).

At first evaluation, 5 patients (9.6%) had more than normal NT-proBNP and 2 patients (40%) of them showed cardiac toxicity. Among the patients with normal baseline NT-proBNP (47 patients), 3 patients (6.4%) interrupted cardiac toxicity. Odds ratio for baseline NT-proBNP was calculated to be 9.78 (P value: 0.015; 95% CI: 1.15-82.90). At second evaluation, 12 patients (23.1%) had more than normal NT-proBNP and 4 patients (33.3%) of them showed cardiac toxicity, while this proportion was 2.5% among patients with normal NT-proBNP at second evaluation (Odds ratio: 19.5, P value: 0.008; 95% CI: 1.97-198.30). AUC for NT-proBNP was calculated to be 0.570 and 0.821 for the first and second evaluation, respectively (P value: 0169, 0.143, respectively). All the data regarding prognostic power of cardiac biomarkers for cardiac toxicity are illustrated in Table **[3](#T3){ref-type="table"}**.

3.4. Sensitivity and Specificity Analysis {#sec3.4}
-----------------------------------------

Youden index was administered to predict an optimal cut-off point for each marker. Data regarding sensitivity and specificity of each marker and optimal cut-off point are shown in Table **[3](#T3){ref-type="table"}**. Overall, among cardiac biomarkers, hs-cTnI showed higher sensitivity, while NT-proBNP had higher specificity for cardiac toxicity. However, between echocardiographic parameters, baseline lateral and inferoseptal SLS had the least sensitivity and lateral and inferoseptal SLS at the second evaluation had the highest specificity (Figs. **2** and **3**).

4. DISCUSSION {#sec4}
=============

Anthracyclines, which are used as a chemotherapy agent in various malignancies, are believed to cause cardiac toxicity, a well-known complication, which hinders the application of them. The incidence of cardiac toxicity ranges between 3% and 48% according to drug and dosage. Several demographic and medical factors predict the risk of developing cardiac toxicity such as age, history of cardiac disease, previous mediastinal radiotherapy and use of other drugs such as trastuzumab \[[@r6], [@r7], 18-[@r20]\]. Early diagnosis and treatment of cardiac toxicity are crucial in improving the prognosis. The management of cardiac toxicity varies widely; however, simple management, such as administering ACE inhibitor in patients with elevated cardiac biomarkers are among them \[[@r21]\]. It is believed that for each doubling in time-to-treatment for this complication, the chance of recovery will decrease by 4-fold and complete recovery is not achieved beyond 6 months \[[@r22]\]. We performed a complete analysis of both cardiac biomarkers and echocardiographic indices. We will discuss them in two main topics.

LVEF mean decreased during our study but reached statistical significance after 3 months, however just 5 patients revealed cardiac toxicity but not clinical symptoms. 7 patients (87.5%) of them who revealed decreased GLS at 4 weeks showed decreased LVEF at 12 weeks. Thus, it can be concluded that GLS may predict LVEF decrease, and to support this hypothesis, we calculated Cohen's kappa coefficient between LVEF at 12 weeks and GLS at 4 weeks. Excellent kappa coefficient supports our hypothesis (kappa: 0.910, p value\<0.001). The longitudinal strain was also described as a predictive factor for both cardiac toxicity and LVEF decrease \< 50% (35). Global longitudinal strain (GLS), for instance, was reported to be a sensitive and specific predictor of cardiac toxicity \[[@r23]\].

Longitudinal strain evaluation was superior to circumferential and radial strain because radial and circumferential contractility may compensate for early longitudinal dysfunction \[[@r15]\]. In the previous animal model, the myocardial strain was also used to predict LVEF reduction \[[@r24]\]. According to previous studies, chemotherapy-induced cardiac toxicity possesses a regional pattern. Some areas may involve and some others compensate for involved segments. Thus, LVEF may remain intact or change slightly, while myocardial cells are damaged \[[@r25]\]. We evaluated SLS in different walls, which were not performed before, as per our knowledge. Inferoseptal SLS had the highest predictive value for cardiac toxicity. Some studies suggest the use of systolic and diastolic volume change as a predictor \[[@r16], [@r26]\]. Baseline left ventricular end-diastolic volume was described to help identify later cardiac events after chemotherapy \[[@r16]\]. In our study, it was interesting that LVESD at first and second evaluation could predict the risk of cardiac toxicity. In one study, it was declared that diastolic parameters are less sensitive than systolic dysfunction for early detection of subclinical cardiotoxicity, which is consistent with our results.

The baseline level of hs-cTnI was higher in the group who showed cardiac toxicity eventually. Another important factor in the highest level of these biomarkers is baseline level. Thus, calculating the hs-cTnI increment from baseline to the highest level may be more suitable \[[@r27]\]. We then calculate the specificity and sensitivity of hs-cTnI increment from baseline to 3 weeks after. Both sensitivity and specificity of this index were lower than absolute level of hs-cTnI at first and second evaluation. We performed a highly sensitive assessment of cTnI, which had higher sensitivity than the former method \[[@r27]\] and was shown to predict cardiac toxicity \[[@r28]-[@r30]\].

LVEF reduction is a late marker of cardiac toxicity and patients with a reduction in LVEF may have irreversible myocardial damage \[[@r31]\]. The well-known study by Cardinal *et al*., first showed that cTnI may predict this LVEF depression \[[@r32]\]. Other subsequent studies discussed the role of this cardiac marker \[[@r33]-[@r36]\]. Moreover, a study proposed that even any detectable level of cTnT as another cardiac marker has clinical features including poor health (9). However, some studies showed that the use of Anthracycline did not cause any elevation in cardiac troponin \[[@r37]\]. In one study, which measured hscTnT, the highest levels of this biomarker were higher in patients with cardiac toxicity than without cardiac toxicity \[[@r27]\]. Another aspect is the baseline level of these markers. The baseline level of these markers may be influenced by patient's factor such as hypertension and renal dysfunction \[[@r38]-[@r41]\]. There were no differences between the two groups with and without cardiac toxicity from this perspective in our study.

In our study, the number of patients with abnormal NT-proBNP increases about two-fold during the 4 months follow-up and their NT-proBNP level predicts the risk of new cardiac toxicity. Assuming 304 pg/ml as a cutoff point for baseline NT-proBNP, the specificity and sensitivity were 97.8% and 40%, respectively. However, sensitivity increased by two-fold when considering the 3-week NT-proBNP  level (cutoff point: 490 pg/ml; LR+: 18.8). NT-proBNP level was not different between the two groups of patients with and without cardiac toxicity. NT-proBNP, was shown to increase throughout treatment with Anthracycline \[[@r42]\]. As Anthracycline-related cardiac toxicity is categorized into acute, early-onset chronic progressive and late-onset chronic progressive \[[@r31]\], the use of time-specific marker to detect cardiac toxicity is important. It was shown that in a large group of asymptomatic long-term survivors of childhood cancer, cTnT level was normal after 15 years of treatment, while abnormal NT-proBNP levels were detected in 13% of this group \[[@r42]\]. This may reflect that NT-proBNP would be used for detecting cardiac damage in long-term follow-up. Ferraro *et al.* suggested 600 pg/ml as the cutoff value. They showed that patients with the NT-proBNP level of more than 600 pg/ml had 3.97 times higher risk of cardiac toxicity \[[@r43]\].  NT-proBNP elevation may stem from other reasons more than cardiac toxicity such as altered cardiac loading conditions and invalidate the use of NT-proBNP for detection of cardiac toxicity \[[@r12]\]. Feola *et al.,* also found that neither baseline nor serial BNP measurement might substitute LVEF monitoring and BNP variation could not predict the change of LVEF \[[@r6]\].

Prevention of cardiotoxicity has been discussed in previous studies. Using less cardiotoxic analogs, prolonging the duration of infusion, and administering cardioprotective agents such as dexrazoxane may decrease the risk of CHF \[[@r44]\].

This study has some limitations. First is the small sample size. These findings may not be applicable to the whole patients' population because of small sample size. The limited number of outcomes (5 patients) defined as cardiac toxicity may reduce the power of this study. The second limitation is that more frequent blood sampling may be needed to identify the time for changes in markers. However, we took blood just 2 times from each patient and the trend of cardiac biomarkers' change may not be exactly illustrated. We just evaluated acute cardiac toxicity; more follow-up is needed to detect late-onset cardiac toxicity. In our study, we could control the demographic factor and other medical conditions between the two groups with and without cardiac toxicity. Moreover, drug dosage was not significantly different between these two groups.

CONCLUSION
==========

The main purpose of this study was to determine the prognostic value of cardiac biomarkers and echocardiographic parameters in early detection of Anthracycline-related cardiac toxicity. This study has shown that hs-cTnI with good sensitivity can predict cardiac toxicity in Anthracycline-based chemotherapy receiver. The use of strain with speckle echocardiography method has a prognostic value; however, both longitudinal and segmental strain should be assessed. As a clinical implication, we suggest a combination of cardiac biomarkers and echocardiographic parameters for early detection of myocardial injury.
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![Two-dimensional longitudinal myocardial strain measurement; Strain measurements were made from three sequential cardiac cycles and then averaged in order to obtain regional strain. The global longitudinal strain (GLS) was obtained by use of Automated Functional Imaging (AFI) of three clips with images of the left ventricle on three apical views and tracing selected points of endocardial border, so that all myocardial segments could be finely visualized in 4-chamber, 2-chamber and 3-chamber views. (*A higher resolution / colour version of this figure is available in the electronic copy of the article*).](CHDDT-20-74_F1){#F1}

![ROC curve for the percentage of inferoseptal SLS change between the first and second evaluation with an AUC of 0.945 (P-value=0.001). (*A higher resolution / colour version of this figure is available in the electronic copy of the article*).](CHDDT-20-74_F2){#F2}

![ROC curve for the percentage of GLS change between the first and second evaluation with an AUC of 0.936 (P-value=0.001). (*A higher resolution / colour version of this figure is available in the electronic copy of the article*).](CHDDT-20-74_F3){#F3}

###### 

Clinical characteristic of patients regarding cardiac toxicity.

  -------------------------------------------------------------------------
  **-**             **Cardiotoxicity**   **-**                      
  ----------------- -------------------- ------------- ------------ -------
  Male              Yes\                 10 (21.2%)\   1 (20.0%)\   0.999
                    No                   37 (78.7%)    4 (80.0%)    

  Smoking           No\                  43 (91.5%)\   4 (80.0%)\   0.410
                    Yes                  4 (8.5%)      1 (20.0%)    

  HTN               No\                  39 (83.0%)\   3 (60.0%)\   0.242
                    Yes                  8 (17.0%)     2 (40.0%)    

  DM                No\                  44 (93.6%)\   5 (100%)\    0.999
                    Yes                  3 (6.4%)      0 (0%)       

  Lung disease      No\                  46 (97.9%)\   5 (100%)\    0.999
                    Yes                  1 (2.1%)      0 (0%)       

  Thyroid disease   No\                  43 (91.5%)\   5 (100%)\    0.999
                    Yes                  4 (8.5%)      0 (0%)       

  HLP               No\                  43 (91.5%)\   5 (100%)\    0.999
                    Yes                  4 (8.5%)      0 (0%)       

  Age               Mean (SD)            44.62\        41.60\       0.566
                                         (11.11)       (11.01)      
  -------------------------------------------------------------------------

**Abbreviations:** HTN: Hypertension; DM: Diabetes Mellitus; HLP: High Lipid Profile.

###### 

Comparison of baseline cardiac biomarkers and echocardiographic parameters between patients with and without cardiotoxicity.

  **-**                  **Cardiotoxicity**   **-**          
  ---------------------- -------------------- -------------- ---------
  **hscTnI**             15.31±2.85           21.40±2.88     \<0.001
  **NT-proBNP**          113.8±115.8          251.8±283.9    0.629
  **GLS**                -21.20±1.76          -20.64±1.39    0.497
  **SLS Inferoseptal**   -20.97±2.32          -20.40±2.07    0.602
  **SLS Inferior**       -20.53±2.47          -20.0±2.00     0.645
  **SLS Anteroseptal**   -20.47±2.51          -21.40±2.30    0.431
  **SLS Anterior**       -20.97±2.05          -20.0±1.22     0.304
  **SLS Lateral**        -20.89±2.31          -19.60±2.88    0.252
  **SLS Posterior**      -18.98±5.86          -20.0±2.24     0.703
  **LVEDD**              4.41±033             4.42±0.31      0.871
  **LVESD**              3.05±0.22            3.32±0.18      0.094
  **LVEDVL**             68.62±8.66           75.00±8.63     0.690
  **Drug dosage**        246.77±89.53         239.2±134.18   0.952

**Abbreviations:** GLS: Global longitudinal strain; SLS: Segmental longitudinal strain; LVEDD: Left ventricular end diastolic diameter; LVESD: Left ventricular end systolic diameter; LVEDVL Left ventricular end diastolic volume.

###### 

Diagnostic characteristics of each marker at first^†^ and second^†^ evaluation.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **-**                  **At First Evaluation**   **At Second Evaluation**                                                                                                
  ---------------------- ------------------------- -------------------------- ------------- ------- ----- ------ ------- ------- ------- -------------- ----- ----- ------ -------
  **hscTnI**             0.940                     0.001                      2.03\         17      100   78.7   4.70    0.979   0.001   1.33\          29    100   91.5   11.75
                                                                              (1.24-3.33)                                                (1.06-1.66)                       

  **NTproBNP**           0.570                     0.609                      1.01\         304     40    97.8   18.80   0.821   0.019   1.01\          490   80    95.7   18.80
                                                                              (1.00-1.01)                                                (1.00-1.01)                       

  **GLS**                0.619                     0.385                      1.21\         -22.4   100   29.8   1.42    0.968   0.001   10.54\         -17   100   85.1   6.71
                                                                              (0.70-2.06)                                                (1.08-102.9)                      

  **SLS Inferoseptal**   0.572                     0.598                      1.14\         -21     60    63.8   1.66    0.93    0.002   2.38\          -17   80    91.5   9.40
                                                                              (0.74-1.66)                                                (1.16-4.85)                       

  **SLS Inferior**       0.581                     0.555                      1.10\         -20     60    66     1.76    0.791   0.033   1.44\          -19   100   57.4   2.35
                                                                              (0.74-1.61)                                                (0.97-2.13)                       

  **SLS Anteroseptal**   0.611                     0.420                      0.85\         -21     80    53.2   1.71    0.777   0.044   1.70\          -19   100   59.6   2.47
                                                                              (0.57-1.26)                                                (0.94-3.04)                       

  **SLS Anterior**       0.670                     0.214                      1.28\         -21.7   100   44.7   1.81    0.798   0.030   1.72\          -20   100   53.2   2.14
                                                                              (0.80-2.04)                                                (0.98-3.00)                       

  **SLS Lateral**        0.634                     0.328                      1.26\         -20     60    76.6   2.56    0.817   0.021   1.05\          -16   60    93.6   9.40
                                                                              (0.84-1.89)                                                (0.94-1.17)                       

  **SLS Posterior**      0.540                     0.768                      0.94\         -19     80    34     1.21    0.806   0.025   1.05\          -19   100   53.2   2.14
                                                                              (0.68-1.29)                                                (0.93-1.18)                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
